Diagnosis and multimodal therapy for hepatocellular carcinoma;Diagnose und multimodale therapie des hepatozellulären karzinoms

Zeitschrift fur Gastroenterologie

Volumn 48, Issue 2, 2010, Pages 274-288

  Kolligs, Frank T ^a   Hoffmann, R T ^a   Op Den Winkel, M ^a   Bruns, C J ^a   Herrmann, K ^a   Jakobs, T F ^a   Lamerz, R ^a   Trumm, C ^a   Zech, C J ^a   Wilkowski, R ^b   Graeb, C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Klinik Bad Trissl   (Argentina)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Radiofrequency ablation; Sorafenib; Transarterial chemo embolisation

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; GENTAMICIN; MITOMYCIN C; MITOXANTRONE; OXALIPLATIN; PLACEBO; SORAFENIB; SUNITINIB;

ADVANCED CANCER; ALGORITHM; CANCER COMBINATION CHEMOTHERAPY; CHEMOEMBOLIZATION; CLINICAL TRIAL; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; RADIATION DOSE; REVIEW;

ACETIC ACID; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; CONTRAST MEDIA; ETHANOL; HEPATECTOMY; HUMANS; IMAGE ENHANCEMENT; INJECTIONS, INTRALESIONAL; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; PALLIATIVE CARE; PATIENT CARE TEAM; PRACTICE GUIDELINES AS TOPIC; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 77749307205     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1109901     Document Type: Review

References (144)

1. Parkin DM, Bray F, Ferlay J et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156
2. Altekruse S, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.J Clin Oncol 2009; 27: 1485-1491
3. London WT, McGlynn KA. Liver cancer In: Schottenfeld D, Fraumeni JF Jr (Hrsg). Cancer Epidemiology and Prevention. New York: Oxford University Press, 2006; 3. Aufl: 763-786
4. Sun CA, Wu DM, Lin CC et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003; 157: 674-682
5. Sakuma K, Saitoh N, Kasai M et al. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology 1988; 8: 1642-1646
6. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468
7. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638
8. Maylin S, Martinot-Peignoux M, Moucari R et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821-829
9. George SL, Bacon BR, Brunt EM et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49: 729-738
10. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-231
11. Bruix J, Sherman M. AASLD Guideline: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236
12. Matsui O. Imaging of multistep human hepatocarcinogenesis by CT during intraarterial contrast injection. Intervirology 2004; 47: 271-276
13. Kelekis NL, Semelka RC, Worawattanakul S et al. Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images. Am J Roentgenol 1998; 170: 1005-1013
14. Hwang GJ, Kim MJ, Yoo HS et al. Nodular hepatocellular carcinomas: detection with arterial-, portal-, and delayed-phase images at spiral CT. Radiology 1997; 202: 383-388
15. Willatt JM, Hussain HK, Adusumilli S et al. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247: 311-330
16. Schacherer D, Girlich C, Jung ME et al. Transabdominal ultrasound with echoenhancement by contrast media in the diagnosis of hepatocellular carcinoma. Dig Dis 2009; 27: 109-113
17. Kim SJ, Kim SH, Lee J et al. Ferucarbotranenhanced 3.0-T magnetic resonance imaging using parallel imaging technique compared with triple-phase multidetector row computed tomography for the preoperative detection of hepatocellular carcinoma. J Comput Assist Tomogr 2008; 32: 379-385
18. Kim YK, Kwak HS, Han YM et al. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography. J Comput Assist Tomogr 2007; 31: 702-711
19. Kim SH, Kim SH, Lee J et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. Am J Roentgenol 2009; 192: 1675-1681
20. Zech CJ, Reiser MF, Herrmann KA. Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis 2009; 27: 114-124
21. Burrel M, Llovet JM, Ayuso C et al. Barcelona Clinic Liver Cancer Group. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an expiant correlation. Hepatology 2003; 38: 1034-1042
22. Stoker J, Romijn MG, de Man RA et al. Prospective comparative study of spiral computer tomography and magnetic resonance imaging for detection of hepatocellular carcinoma. Gut 2002; 51: 105-107
23. Marin D, Di Martino M, Guerrisi A et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology 2009; 251: 85-95
24. Kim KY, Kim CS, Chung GH et al. Comparison of Gadobenate Dimeglumine-Enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. Am J Roentgenol 2006; 186: 149-157
25. Choi SH, Lee JM, Yu NC et al. Hepatocellular carinoma in liver transplantation candidates: detection with Gadobenate Dimeglumine-enhanced MRI. Am J Roentgenol 2008; 191: 529-536
26. Kim SH, Choi BI, Lee JY et al. Diagnostic Accuracy of Multi-/single-De-tector row CT and contrast-enhanced MRI in the detection of hepatocellular carcinomas meeting the Milan criteria before liver transplantation. Intervirology 2008; 51: 52-60
27. Wang JH, Lu SN, Hung CH et al. Small hepatic nodules (≤ 2 cm) in cirrhosis patients: characterization with contrast-enhanced ultrasonography. Liver international 2006; 26: 928-934
28. Dai Y, Chen MH, Fan ZH et al. Diagnosis of small hepatic nodules detected by surveillance ultrasound in patients with cirrhosis: Comparison between contrast-enhanced ultrasound and contrast-enhanced helical computed tomography. Hepatology Res 2008; 38: 281-290
29. Park JW, Kim JH, Kim SK et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008; 49: 1912-1921
30. Lamerz R, Hayes P, Hoffmann RT et al. NACB: Practice guidelines and recommendations for use of tumour markers in the clinic-Liver Cancer Manuscript (3D) 2005. http://www.nacb.org/Impg/tumour-lmpg-draft.stm
31. Chen D, Sung J, Shen J et al. Serum alpha-fetoprotein in early stages of human hepatocellular carcinoma. Gastroenterology 1984; 86: 1404-1409
32. Soreide O, Czerniak A, Bradpiece H et al. Characteristics of fibrolamellar hepatocellular carcinoma. A study of nine cases and review of the literature. Am J Surg 1986; 151: 518-523
33. Fasani P, Sangiovanni A, De Fazio C et al. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 1999; 29: 1704-1707
34. Mita Y, Aoyagi Y, Yanagi M et al. The usefulness of determining desgamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998; 82: 1643-1648
35. Okuda H, Nakanishi T, Takatsu K et al. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 1999; 85: 812-818
36. Tanaka Y, Kashiwagi T, Tsutsumi H et al. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma. Hepatogastroenterology 1999; 46: 2464-2468
37. Okuda H, Nakanishi T, Takatsu K et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 2000; 88: 544-549
38. Marrero JA, Su GL, Wei W et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003; 37: 1114-1121
39. Capurro M, Wanless IR, Sherman M et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97
40. Sung YK, Hwang SY, Park MK et al. Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 2003; 94: 259-262
41. Hippo Y, Watanabe K, Watanabe A et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004; 64: 2418-2423
42. Marrero JA, Romano PR, Nikolaeva O et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocullular carcinoma. J Hepatol 2005; 43: 1007-1012
43. Ishizawa T, Hasegawa K, Aoki T et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-1916
44. Shirabe K, Shimada M, Gion T et al. Postoperative liver failure after ajor hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg 1999; 188: 304-309
45. Okamoto E, Kyo A Yamanaka N et al. Prediction of the safe limits of hepatectomy by combined volumetric and functional measurements in patients with impaired hepatic function. Surgery, 1984; 95: 586-592
46. Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg 2001; 88: 165-175
47. Farges O, Belghiti J, Kianmanesh R et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003; 237: 208-217
48. Sasaki A, lwashita Y, Shibata K et al. Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol 2006; 32: 773-779
49. Helmberger T, Dogan S, Straub G et al. Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. Digestion 2007; 75: 104-112
50. Regimbeau JM, Kianmanesh R, Farges O et al. Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. Surgery 2002; 131: 311-317
51. Fan ST, Lo CM, Liu CL et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999; 229: 322-330
52. Poon RJ, Ng IO, Fan ST et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 2001; 19: 3037-3044
53. Morris-Stiff G, Gomez D, de Liguori Carina N et al. Surgical management of hepatocellular carcinoma: Is the jury still out? Surg Oncol 2009; 18: 298-321
54. Portolani N, Coniglio A, Ghidoni S et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006; 243: 229-235
55. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699
56. Iwatsuki S, Starzl TE, Sheahan DG et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214: 221-228
57. Colella G, Bottelli R, De Carlis L et al. Hepatocellular carcinoma: comparison between liver transplantation, resective surgery, ethanol injection, and chemoembolization. Transpl Int 1998; 11: 193-196
58. Yoo HY, Patt CH, Geschwind JF et al. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003; 21: 4329-4335
59. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8: 765-774
60. Mazzaferro V, Llovet JM, Miceli R et al. Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43
61. Decaens T, Roudot-Thoraval F, Bresson-Hadni S et al. Impart of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005; 11: 767-775
62. Chapman WC, Majella Doyle MB, Stuart JE et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation, Ann Surg 2008; 248: 617-625
63. Ebara M, Okabe S, Kita K et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 2005; 43: 458-464
64. Lencioni R, Crocetti L. Image-guided thermal ablation of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2008; 66: 200-207
65. Lencioni R, Bartolozzi C, Caramella D et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients. Cancer 1995; 76: 1737-1746
66. Livraghi T, Giorgio A, Marin C et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995; 197: 101-108
67. Chen MS, Li JQ, Zheng Y et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of Surgery 2006; 243: 321-328
68. Koda M, Murawaki Y, Mitsuda A et al. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer 2000; 88: 529-537
69. Lencioni RA, Allgaier HP, Cioni D et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-240
70. Lin SM, Lin CJ, Lin CC et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 1151-1156
71. Shiina S, Teratani T, Obi S et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-130
72. Choi D, Lim HK, Rhim H et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. European Radiology 2007; 17: 684-692
73. Lencioni R, Cioni D, Crocetti L et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005; 234: 961-967
74. Tateishi R, Shiina S, Teratani T et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103: 1201-1209
75. Livraghi T, Meloni F, Di Stasi M et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008; 47: 82-89
76. Yin XY, Xie XY, Lu MD et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer 2009; 115: 1914-1923
77. Marelli L, Stigliano R, Triantos C et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25
78. Wang JH, Changchien CS, Hu TH et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. Eur J Cancer 2008; 44: 1000-1006
79. Varela M, Real MI, Burrel M et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-481
80. Comma C, Schepis F, Orlando A et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54
81. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917
82. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739
83. Bruix J, Llovet JM, Castells A et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-1583
84. Chang JM, Tzeng WS, Pan HB et al. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 1994; 74: 2449-2453
85. Kawai S, Okamura J, Ogawa M et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma-a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1992; 31 (Suppl): 1-6
86. Lencioni R, Malagarl K, Vogl T et al. A randomized phase II trial of a drug eluting bead in the treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization. J Clin Oncol 2009; 27: 4523
87. Kulik LM, Carr BI, Mulcahy MF et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81
88. Ho S, Lau WY, Leung TW et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997; 24: 293-298
89. Lau WY, Ho S, Leung TW et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998; 40: 583-592
90. Lau WY, Ho S, Leung WT et al. What determines survival duration in hepatocellular carcinoma treated with intraarterial Yttrium-90 microspheres? Hepatogastroenterology 2001; 48: 338-340
91. Sangro B, Bilbao JI, Boan J et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 792-800
92. Geschwind JF, Salem R, Can BI et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127: 194-205
93. Salem R, Lewandowski RJ, Atassi B et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16: 1627-1639
94. Kulik LM, Atassi B, van Holsbeeck L et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94: 572-586
95. Lawrence TS, Robertson JM, Anscher MS et al. Hepatic toxicity resulting from cancer treatment. Int J Rad Oncol Biol Phys 1995; 31: 1237-1248
96. Lawrence TS, Ten Haken R, Kessler M. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Rad Oncol Biol Phys 1992; 23: 781-788
97. Phillips R, Murikami K. Primary neoplasma of the liver. Results of radiation therapy. Cancer 1960; 13: 714-720
98. Notsumata K, Okazaki A, Yokohama T. Radiotherapy for advanced hepatocellular carcinoma. Acta Hepatol Jpn 1992; 33: 611-616
99. Takagi H, Takayama H, Yamada S. Radiation therapy to the hepatocellular carcinoma. Jpn J Gastroenterol 1989; 86: 237-245
100. Tang ZY. Treatment of primary liver cancer - with special reference to the east part of china. Ann Acad Med 1980; 9: 251-262
101. Li B, Yu J, Wang L et al. Study of local three-dimensional conformai radiotherapy combined with transcatheter arterial chemoembolization for patients with Stage III hepatocellular carcinoma. Am J Clin Oncol 2003; 26: e92-e99
102. Cheng JC, Wu JK, Huang CM et al. Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2003; 56: 229-234
103. Guo WJ, Yu EX, Liu LM et al. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol 2003; 9: 1697-1701
104. Yamada K, Izaki K, Sugimoto K et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003; 57: 113-119
105. Wu DH, Liu L, Chen LH. Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2004; 10: 2184-2189
106. Park W, Lim DH, Paik SW et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005; 61: 1143-1150
107. Louafi S, Boige V, Ducreux M et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007; 109: 1384-1390
108. Becker G, Allgaier HP, Olschewski M et al. HECTOR Study Group. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007; 45: 9-15
109. Kawata S, Yamasaki E, Nagase T et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001; 84: 886-891
110. Abou-Alfa GK, Schwartz L, Rica S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300
111. Llovet JM, Ricci S, Mazzafeno V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
112. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34
113. So BJ, Bekaii-Saab T, Bloomston MA et al. Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report. Journal of Hematology and Oncology 2008; 1: 18
114. Llovet J, Mena C, Shan M et al. Biomarkers predicting outcome of patients with hepatocellular carcinoma: results from the randomized phase III sharp trial. Hepatology 2008; 48 (Suppl): 372A (abstract 149)
115. Perforierte Ulzerationen der Speiseröhre und Mediastinitis mit Todesfolge nach Sorafenib (Nexavar). Deutsches Ärzteblatt 2009; 106: A476
116. Miller AA, Murry DJ, Owzar K et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009; 27: 1800-1805
117. Zhu AX, Sahani DV, Duda DG et al. Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. J Clin Oncol 2009; 27: 3027-3035
118. Siegel AB, Cohen EI, Ocean A et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26: 2992-2998
119. Thomas MB, Chadha R, Glover K et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110: 1059-1067
120. Philip PA, Mahoney MR, Allmer C et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657-6663
121. Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 1898-1903
122. Thomas MB, Morris JS, Chadha R et al. Phase II Trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27: 843-850
123. Zhu AX, Stuart K, Blaszkowsky LS et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 581-589
124. Park BH, Hwang T, Liu TC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008; 9: 533-542
125. Liu TC, Hwang T, Park BH et al. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008; 16: 1637-1642
126. Yamasaki S, Hasegawa H, Kinoshita H et al. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 1996; 87: 206-211
127. Wu CC, Ho YZ, Ho WL et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995; 82: 122-126
128. Sala M, Llovet JM, Vilana R et al. Barcelona Clinic Liver Cancer Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40: 1352-1360
129. Cammà C, Di Marco V, Orlando A et al. Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol 2005; 42: 535-540
130. Zhang YJ, Liang HH, Chen MS et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology 2007; 244: 599-607
131. Lencioni R, Pinto F, Armillotta N et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol 1997; 7: 514-519
132. Arii S, Yamaoka Y, Futagawa S et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224-1229
133. Taniguchi M, Kim SR, Imoto S et al. Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1997-2002
134. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-1261
135. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171
136. Sciarrino E, Simonetti RG, Le Moli S et al. Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer 1985; 56: 2751-2755
137. Lai CL, Wu PC, Chan GC et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62: 479-483
138. Lee J, Park JO, Kim WS et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004; 54: 385-390
139. Yeo W, Mok TS, Zee B et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 19: 1532-1538
140. Yang TS, Lin YC, Chen JS et al. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000; 89: 750-756
141. Patt YZ, Hassan MM, Aguayo A et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004; 101: 578-586
142. Boige V, Raoul JL, Pignon JP et al. Fédération Francophone de Cancérologie Digestive. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03 - 03 trial. Br J Cancer 2007; 97: 862-867
143. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009; 373: 614-616
144. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327